Evidence map›Paper›PMID 40303290›Full record

ArticleInternational journal of biological sciences2025

YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.

Lingxiao Wang, Shiguang Yang, Jie Li, Yuan Fang, Mengzhou Guo, Xiaojing Du, Li Song, Sinuo Chen, Xingxing Zhang, Zhuoran Qi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Functional roles and mechanisms of NAT10-mediated RNA acFrontiers in cell and developmental biology · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lingxiao WangDepartment of General Pediatrics, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Shiguang YangDepartment of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University, Shanghai, China.
Jie LiNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan FangDepartment of Liver Surgery, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital,Fudan University, Shanghai, China.
Mengzhou GuoDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaojing DuEndoscopy Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Li SongNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Sinuo ChenNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xingxing ZhangDepartment of Gastroenterology, Shanghai Jiaotong University Affiliated Sixth People Hospital South Campus, Shanghai, China.
Zhuoran QiNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Kaihui ZhangInstitute of Pediatric Research, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Bei LvDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jinglin XiaNational Medical Center & National Clinical Research Center for Interventional Medicine, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatoblastoma (HB) is the most common malignant liver tumor in children, with limited treatment options. The N4-acetylcytidine (ac4C) modification, an important mRNA post-transcriptional modification catalyzed by N-acetyltransferase 10 (NAT10), plays a crucial role in the initiation and progression of tumors. However, its impact on the development and prognosis of HB is largely unknown. This study demonstrates that NAT10 is notably upregulated in HB. NAT10 inhibition suppressed HB proliferation and metastasis

Indexed as

Adaptor Proteins, Signal TransducingHepatoblastomaLiver NeoplasmsN-Terminal Acetyltransferase EPentose Phosphate PathwayTranscription FactorsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGlucosephosphate DehydrogenaseHumansMiceMice, Inbred BALB CMice, NudeYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingGlucosephosphate DehydrogenaseN-Terminal Acetyltransferase ETranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsG6PDhepatoblastomaN4-acetylcytidineNAT10pentose phosphate pathwayYAP1

Identifiers

PMID40303290
PMCPMC12035897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.